Menu Icon Created with Sketch Beta.


Adam Goulburn

Previous Post Left arrow Next Post Right Arrow
Nature is far smarter than we are.


Adam invests at the intersection of biology, healthcare, technology and data. He is interested in the digitization of healthcare; genomics and coding biology; the microbiome; bionics and cyborgs; neuroscience and brain-computer interfaces; next-gen bio-imaging; regenerative medicine; synthetic biology; human performance; and other areas of applied hard sciences.

Over the past decade, Adam has been an integral part of the firm’s life sciences investments, focusing on futuristic ventures at the edge of possibility. Adam founded and incubated a number of Lux companies including Cajal Neuroscience and VNV Bio. He was also the founding CEO and investor in Kallyope, which combines bioinformatics, sequencing, neuroimaging and molecular biology to decode the gut-brain axis. In addition, Adam was a founding investor in Eikon Therapeutics, which deploys next-generation microscopy and single-molecule imaging for high-throughput drug discovery. 

Fascinated with the potential of digitization in life sciences and the broader healthcare ecosystem, Adam has led a number of investments in healthcare and biotechnology companies, including Science 37 (virtual clinical trials), AllStripes (acceleration of rare disease drug discovery) and Rivet (healthcare payment transparency platform), Everly Health (home testing platform), Adimab (antibody drug discovery), Plexium (targeted protein degraders), Atavistik Bio (metabolite-protein interactions), and Gandeeva (cryo-electron microscopy). Adam also led Lux’s investments in Senti Biosciences, Pager, Zipdrug, Workit Health, Physera, Mahana Therapeutics, Aptible, Vesta Healthcare, Drone Racing League, and has worked with Variant, Strateos and Kyruus. 

Prior to joining Lux in 2011, Adam was a Postdoctoral Fellow of Neuroscience at Weill Cornell Medical College, researching regenerative stem cell medicine in association with brain disorders such as schizophrenia and Alzheimer’s disease. Originally from Australia, Adam has dual undergraduate degrees in Business and Science and a PhD from the Australian Stem Cell Centre, where he was a Premier Scholar. He has been published in numerous peer-reviewed, scientific journals.

What debates do you have most frequently with your partners?
How can you build a computer to replicate the human mind when we still don’t understand how the brain works?

What does the future look like?
More intelligent cities, buildings, vehicles and clothing. Personalized nutrition and medicine; printable food, drugs and DNA. Deeper interplanetary travel and exploration. Blurred lines between real and virtual worlds.

What is the most exciting innovation of the past decade?
The creation of induced pluripotent (iPS) cells, which have the potential to turn any cell into a regenerative stem cell; CRISPR technology and DNA editing.

Key Facts

  • Has travelled to 40+ countries, including Ulan Bator, Mongolia, with average winter lows of -40F

  • Created a “glowing” gene research tool to track neural cells in crowded, heterogeneous petri dishes

  • Represented Australia at the Maccabiah Games (‘Jewish’ Olympics) for soccer

Nature is far smarter than we are.